Literature DB >> 7473721

Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops.

J Xiang1, Y Sha, Z Jia, L Prasad, L T Delbaere.   

Abstract

Structural analysis derived from the crystallographic study of the chimeric B72.3 antibody illustrated that some heavy-chain framework residues having atomic interactions with heavy-chain CDR residues may directly affect the conformation of CDR loops. For example, an alanine residue at H71 provides room for packing CDR2/CDR1 and lysine residues at H73 and H93 contribute a salt-bridge to aspartic acid at H55 in CDR2 and a hydrogen bond to the carbonyl group at H96 in CDR3, respectively. We have analysed the contribution of these framework residues to the TAG72-binding affinity. We altered these framework residues by site-directed mutagenesis, and determined the affinity of these mutant chimeric antibodies for the TAG72 antigen by solid phase radioimmunoassay. We found that a single amino acid substitution of alanine by phenylalanine at H71 or lysine by isoleucine at H93, significantly reduced the binding affinity for the TAG72 antigen by 12 and 20-fold, respectively, whereas the substitution of lysine by alanine at H73 reduced the binding affinity only two-fold. Our results indicate that heavy-chain framework residues alanine at H71 and lysine at H93 of the chimeric B72.3 antibody are the major determinants of the conformation of heavy-chain CDR2/CDR1 and CDR3 loops, whereas the salt-bridge between lysine at H73 and aspartic acid at H55 is less important. The hydrogen bond between two framework residues, glutamine at H5 and serine at H25 does not affect any CDR conformation. Our results will thus be of importance especially when the humanized B72.3 antibody is constructed by grafting the CDR loops to a human framework. The important framework region interactions must be maintained in the final humanized antibody.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7473721     DOI: 10.1006/jmbi.1995.0560

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  8 in total

1.  Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: Rationale and examples.

Authors:  Yi-Fan Zhang; Mitchell Ho
Journal:  MAbs       Date:  2017-02-06       Impact factor: 5.857

Review 2.  The structural basis of antibody-antigen recognition.

Authors:  Inbal Sela-Culang; Vered Kunik; Yanay Ofran
Journal:  Front Immunol       Date:  2013-10-08       Impact factor: 7.561

3.  Complementarity determining regions and frameworks contribute to the disulfide bond independent folding of intrinsically stable scFv.

Authors:  Anna Gąciarz; Lloyd W Ruddock
Journal:  PLoS One       Date:  2017-12-18       Impact factor: 3.240

4.  Adaption of human antibody λ and κ light chain architectures to CDR repertoires.

Authors:  Rob van der Kant; Joschka Bauer; Anne R Karow-Zwick; Sebastian Kube; Patrick Garidel; Michaela Blech; Frederic Rousseau; Joost Schymkowitz
Journal:  Protein Eng Des Sel       Date:  2019-12-13       Impact factor: 1.650

5.  Mutation of Framework Residue H71 Results in Different Antibody Paratope States in Solution.

Authors:  Monica L Fernández-Quintero; Katharina B Kroell; Florian Hofer; Jakob R Riccabona; Klaus R Liedl
Journal:  Front Immunol       Date:  2021-03-02       Impact factor: 7.561

6.  Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme.

Authors:  J Krauss; M A E Arndt; Z Zhu; D L Newton; B K Vu; V Choudhry; R Darbha; X Ji; N S Courtenay-Luck; M P Deonarain; J Richards; S M Rybak
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

7.  An efficient visualization tool for the analysis of protein mutation matrices.

Authors:  Maria Pamela C David; Carlo M Lapid; Vincent Ricardo M Daria
Journal:  BMC Bioinformatics       Date:  2008-04-28       Impact factor: 3.169

8.  Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma.

Authors:  Yi-Fan Zhang; Mitchell Ho
Journal:  Sci Rep       Date:  2016-09-26       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.